Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.57% | 30.54% | 39.50% | 73.53% | 73.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.57% | 30.54% | 39.50% | 73.53% | 73.59% |
| Cost of Revenue | 17.91% | 30.27% | 37.90% | 31.30% | 36.46% |
| Gross Profit | 21.20% | 30.60% | 39.86% | 85.47% | 85.47% |
| SG&A Expenses | 20.88% | 13.33% | 13.18% | 14.34% | 3.71% |
| Depreciation & Amortization | 1,160.57% | 91.11% | 0.00% | -0.04% | 1.13% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.77% | 14.60% | 13.45% | 15.00% | 6.64% |
| Operating Income | -410.47% | 171.58% | 152.69% | 123.69% | 82.64% |
| Income Before Tax | -955.48% | 410.31% | 220.50% | 142.03% | 91.47% |
| Income Tax Expenses | -1,040.00% | -4,471.79% | 18,690.63% | -6,562.50% | 221.43% |
| Earnings from Continuing Operations | -920.05% | 471.71% | 132.86% | 147.50% | 91.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -920.05% | 471.71% | 132.86% | 147.50% | 91.32% |
| EBIT | -410.47% | 171.58% | 152.69% | 123.69% | 82.64% |
| EBITDA | 186.16% | 503.37% | 233.31% | 146.14% | 92.56% |
| EPS Basic | -879.93% | 457.44% | 131.68% | 145.94% | 91.60% |
| Normalized Basic EPS | -859.01% | 377.04% | 216.11% | 140.65% | 91.75% |
| EPS Diluted | -879.93% | 429.25% | 130.77% | 144.13% | 91.62% |
| Normalized Diluted EPS | -859.01% | 357.99% | 209.99% | 139.10% | 91.75% |
| Average Basic Shares Outstanding | 4.09% | 4.05% | 3.75% | 3.42% | 3.30% |
| Average Diluted Shares Outstanding | 4.09% | 11.73% | 9.57% | 7.50% | 3.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |